Genotypic and phenotypic resistance: Longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation

American Journal of Gastroenterology

Volumn 98, Issue 1, 2003, Pages 151-159

  Ben Ari, Ziv ^a,b,c   Daudi, Nili ^a,b   Klein, Athalia ^a,b   Sulkes, Jaqueline ^a,b   Papo, Orit ^a,b   Mor, Eytan ^a,b   Samra, Zmira ^a,b   Gadba, Rachamim ^a,b   Shouval, Daniel ^a,b   Tur Kaspa, Ran ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DNA POLYMERASE; HEPATECT R; HEPATITIS B ANTIBODY; INTERFERON; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMRIHEP B; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA HYBRIDIZATION; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; MONITORING; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VIREMIA; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

ADULT; CHILD; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037253772     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07178.x     Document Type: Article

References (42)

1. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;19:8495-9.
2. Xie H, Voronkov M, Liotta DC, et al. Phosphatidyl-2′,3′-dedeoxy-3′-thiacytidine: Synthesis and activity in hepatitis B and HIV-1-infected cells. Antiviral Res 1995;28:113-20.
3. Severni A, Liu X, Wilson JS, et al. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dedeoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995;39:1430-5.
4. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B infection in the United States. N Engl J Med 1999;341:1256-63.
5. Gordon D, Walsh JH. Hepatitis drugs win approval. Gastroenterology 1998;116:235-6.
6. Lai CL, Chine RW, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
7. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;384:1212-5.
8. Ben-Ari Z, Shmueli D, Mor E, et al. Beneficial effects of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;63:393-6.
9. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-6.
10. Lai CL. Antiviral therapy for hepatitis B and C in Asians. J Gastroenterol Hepatol 1999;14:S19-S21.
11. Lau DTY. Long-term lamivudine therapy for chronic hepatitis B. Antiviral Ther 2000;5:43-52.
12. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
13. Ben-Air Z, Mor E, Shapira Z, et al. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transplant 2001;7:113-7.
14. Tipples GA, Ma MM, Fischer KP, et al. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
15. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
16. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
17. Allen MI, DesLauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
18. Niesters HG, Honkoop P, Haagsma EB, et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-5.
19. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
20. Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
21. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998;29:151-68.
22. Seta T, Yokosuka O, Imazeki F, et al. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000;60:8-16.
23. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-55.
24. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-33.
25. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999;80:601-6.
26. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-45.
27. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
28. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver of transplant recipients. Gut 2000;46:107-13.
29. Ben-Ari Z, Pappo O, Zemel R, et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999;68:232-6.
30. Ahmed SI, Tavan D, Pichoud C, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.
31. Tur-Kaspa R, Klein A, Aharonson SH. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992;16:1338-42.
32. Gerken G, Gomes J, Lampertico P, et al. Clinical evaluation and applications of the amplicor HBV monitor TM test, a quantitative HBV DNA PCR assay. J Virol Methods 1998;74:155-65.
33. Ben-Ari Z, Zemel R, Kazetsker A, et al. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Am J Gastroenterol 1999;94:663-7.
34. Lindth M, Andersson AS, Gusdal A. Genotypes, nt1858 variants, and geographic origin of hepatitis B virus. Large-scale analysis using a new genotypic method. J Infect Dis 1997; 175:1285-93.
35. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-47.
36. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for accessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
37. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
38. Zhou T, Saputelli J, Aldrich CE, et al. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 1999;43:1947-54.
39. Terrault N, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28:555-61.
40. Zollner B, Peterson J, Schroter M, et al. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 20001;357:934-5.
41. Gunther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-37.
42. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.